{"entity":{"id":"cul7","kind":"target","name":"CUL7","aka":["cullin 7","Cullin-7","dJ20C7.5","KIAA0076"],"tldr":"CUL7 (Cullin-7) is a gene. The public catalogues list it as a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Glioma & glioblastoma.","summary":"Core component of the 3M and Cul7-RING(FBXW8) complexes, which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. Core component of the 3M complex, a complex required to regulate microtubule dynamics and genome integrity. It is unclear how the 3M complex regulates microtubules, it could act by controlling the level of a microtubule stabilizer.\n\nCIViC holds 2 clinical evidence items and 0 assertions across 1 variant.","asOf":"2026-09-23","links":[{"label":"HGNC HGNC:21024","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21024"},{"label":"UniProt Q14999","url":"https://www.uniprot.org/uniprotkb/Q14999/entry"},{"label":"NCBI Gene 9820","url":"https://www.ncbi.nlm.nih.gov/gene/9820"},{"label":"Ensembl ENSG00000044090","url":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000044090"}],"tags":["cancer-genes-wave"],"related":["civic"],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC holds 2 clinical evidence items on its variants. Evidence tier \"clinical-evidence\" is the strongest of those signals.","Prevalence not recorded: none of the sources gives a positivity rate.","Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Brain Glioma."],"provenance":{"editedBy":"scripts/fetch-cancer-genes.ts (CIViC, Open Targets, IntOGen, HGNC, UniProt)","editedOn":"2026-09-23"},"symbol":"CUL7","role":["biomarker"],"evidenceTier":"clinical-evidence","sources":[{"label":"HGNC HGNC:21024","url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:21024","note":"approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)"},{"label":"UniProt Q14999","url":"https://www.uniprot.org/uniprotkb/Q14999/entry","note":"protein name, function text, keywords and locations (REST API)"},{"label":"CIViC gene CUL7","url":"https://civicdb.org/features/7780","note":"2 evidence items, 0 assertions, 1 variants; diseases: Glioblastoma, Brain Glioma (GraphQL API, CC0)"}],"specificity":"broadly-expressed","distribution":"one-type","specificityNote":"Broadly expressed or essential: HPA finds the RNA at low tissue specificity; a medicine acting on the wild-type protein would expose normal tissue too. HPA CUL7: RNA low tissue specificity; high antibody staining in 2 normal tissues; highest cancer staining stomach cancer (1 of 8 high). Distribution: 1 cancer family in the corpus carries a prevalence row, label threshold or catalogue link for it (Brain and spinal cord tumours (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)","specificitySources":[{"label":"Human Protein Atlas CUL7 tissue","url":"https://www.proteinatlas.org/ENSG00000044090-CUL7/tissue","note":"RNA tissue and blood lineage specificity, normal tissue antibody staining (version 25.1, CC BY-SA 3.0)"},{"label":"Open Targets ENSG00000044090 associations","url":"https://platform.opentargets.org/target/ENSG00000044090/associations","note":"cancer associations at or above 0.5 (CC0)"}],"hgnc":"HGNC:21024","ensembl":"ENSG00000044090","uniprot":"Q14999","entrez":"9820","firstDescribed":1994,"firstDescribedBasis":"sequence","firstDescribedNote":"Earliest sequence paper UniProt cites for the protein: Nomura et al, DNA Res, 1994, \"Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1\".","firstDescribedSource":"https://pubmed.ncbi.nlm.nih.gov/7584044/","biology":"Core component of the 3M and Cul7-RING(FBXW8) complexes, which mediate the ubiquitination and subsequent proteasomal degradation of target proteins. Core component of the 3M complex, a complex required to regulate microtubule dynamics and genome integrity. It is unclear how the 3M complex regulates microtubules, it could act by controlling the level of a microtubule stabilizer. The Cul7-RING(FBXW8) complex alone lacks ubiquitination activity and does not promote polyubiquitination and proteasomal degradation of p53/TP53. However it mediates recruitment of p53/TP53 for ubiquitination by neddylated CUL1-RBX1. Interaction with CUL9 is required to inhibit CUL9 activity and ubiquitination of BIRC5. Location: Cytoplasm; Cytoplasm, cytoskeleton, microtubule organizing center, centrosome; Cytoplasm, perinuclear region; Golgi apparatus (UniProt). Locus 6p21.1 (HGNC).","whereFound":["Glioma & glioblastoma: CIViC evidence names this disease"],"targetClass":"other","prevalence":[]},"route":"/targets/cul7/","neighbours":{"collection":[{"id":"civic","kind":"collection","name":"CIViC","route":"/collections/civic/"}],"cancer":[{"id":"glioblastoma","kind":"cancer","name":"Glioma & glioblastoma","route":"/cancers/glioblastoma/"}]}}